An Exploratory Phase I Study With Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Sorafenib (Primary) ; Vinflunine (Primary)
- Indications Bladder cancer; Pelvic cancer; Urethral cancer; Urogenital cancer
- Focus Adverse reactions
- Acronyms VINSOR
- 28 Dec 2017 Planned End Date changed from 1 Mar 2017 to 1 Apr 2018.
- 28 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2016 Planned End Date changed from 1 Jan 2016 to 1 Mar 2017.